Trial Profile

An Observational Pregnancy Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA (Inebilizumab-cdon) During Pregnancy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inebilizumab (Primary)
Indications Neuromyelitis optica
Focus Adverse reactions
Sponsors Amgen; Horizon Pharma USA

Most Recent Events

19 Feb 2025 Planned initiation date (estimated date for recruitment of the first subject) changed from 14 Feb 2025 to 14 Apr 2025.
12 Dec 2024 Planned initiation date changed from 16 Nov 2024 to 14 Feb 2025.
07 Oct 2024 Planned End Date changed from 1 Aug 2032 to 31 Oct 2032.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com